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Proton pump inhibitors and histamine-2-receptor antagonists and
pancreatic cancer risk: a nested case–control study
MC Bradley*,1, LJ Murray2, MM Cantwell2 and CM Hughes1
1Clinical and Practice Research Group, School of Pharmacy, Queen’s University Belfast, 97 Lisburn Road, Belfast, Northern Ireland BT9 7BL, UK ; 2Cancer
Epidemiology and Health Services Research Group, Centre for Public Health, Queen’s University Belfast, Institute for Clinical Sciences, Royal Victoria
Hospital, Belfast, Northern Ireland, BT12 6BJ, UK
BACKGROUND: The relationship between use of proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2RAs) and
pancreatic cancer risk has yet to be examined. Data from a range of studies suggest biologically plausible mechanisms, whereby these
drugs (or the conditions for which they are prescribed) may affect pancreatic cancer risk. The objective of this study was to
investigate the relationship between use of PPIs/H2RAs and pancreatic cancer risk.
METHODS: A nested case–control study was conducted within the UK general practice research database (GPRD). Cases had a
diagnosis of exocrine pancreatic cancer and controls were matched to cases on general practice site, sex and year of birth. Exposure
to PPIs and to H2RAs since entry into GPRD until 2 years before the diagnosis date (corresponding date in controls) and in the
5 years before the diagnosis date were separately assessed. Conditional logistic regression analyses were used to generate odds ratios
(ORs) and 95% confidence intervals (CIs) associated with PPI or H2RA use compared with nonuse.
RESULTS: Ever use of PPIs since entry into the GPRD (excluding the 2 years prior to diagnosis) was not associated with risk of
pancreatic cancer; OR (95% CI) 1.02 (0.85–1.22). Neither the dose nor the duration of PPI or H2RA use was associated with
pancreatic cancer risk. No consistent patterns of association were seen when cumulative exposure (dose and duration) to these
drugs was examined separately or together.
CONCLUSION: PPI/H2RA use, in a UK population, was not associated with pancreatic cancer risk.
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Pancreatic cancer is rapidly fatal and is the fifth leading cause of
cancer mortality in the western world. Almost 50% of patients
present with distant metastases and little progress has been made
in recent decades in the diagnosis or treatment of this cancer,
resulting in poor survival rates (Jemal et al, 2007).
Proton pump inhibitors (PPIs) are some of the most commonly
prescribed medications in North America (IMS Health, 2008) and
the United Kingdom (National Health Service Business Services
Authority, 2009). They are used in the treatment of gastrointestinal
disorders, such as gastro-oesophageal reflux disease (DeVault and
Castell, 2005; BMJ group, 2009). PPIs are potent suppressors of
gastric acid and recently they have been used with increased
frequency and for prolonged durations (Naunton et al, 2000).
The long-term gastric hypoacidity associated with PPI use results
in raised serum gastrin levels (hypergastrinaemia) (Klinkenberg-
Knol et al, 1994). Histamine-2-receptor antagonists (H2RAs) are
also used for similar indications, have been in use since the
1970s, and may induce hypergastrinaemia and hypoacidity (Wynn
et al, 2007).
There are a number of potential mechanisms, whereby use of
PPIs/H2RAs may influence pancreatic cancer risk (Risch, 2003).
Gastric hypoacidity favours the overgrowth of bacteria in the
stomach (Fried et al, 1994; Thorens et al, 1996), which results in
the production of N-nitrosamines (Yeomans et al, 1995), although
there is some evidence to the contrary (Vermeer et al, 2001).
Pancreatic ductal adenocarcinomas have been seen to develop in
mice and human pancreatic cells exposed to nitrosamines (Parsa
et al, 1981; Parsa, 1987). PPI-/H2RA-related hypergastrinaemia
may also contribute to pancreatic cancer carcinogenesis. Gastrin
appears to have a role in the development and progression of
gastrointestinal malignancies (Chao and Hellmich, 2010). Gastrin
receptors are expressed in human pancreatic cancer cells (Smith
et al, 1994), and gastrin has been seen to stimulate the growth of
human pancreatic cancer cells in culture and in tumours
transplanted into nude mice (Smith et al, 1995). These effects
were blocked by gastrin-receptor antagonists (Smith et al, 1995),
such as gastrazole (Roberts et al, 2002), which in a small
randomised controlled trial increased the survival time among
pancreatic cancer patients (Chau et al, 2006) Other studies refute
this theory (Chu et al, 1997).
PPI/H2RA use increases secretin levels, which may influence
pancreatic cell growth (Sarfati et al, 1985; Howatson and Carter,
1987).
The relationship between use of PPI/H2RAs and pancreatic
cancer risk has yet to be examined, despite widespread use of these
drugs and data from a range of studies suggesting biologically
plausible mechanisms, whereby these drugs (or the conditions
for which they are prescribed) may affect pancreatic cancer risk.
We examined this relationship in a large nested case– control
study within the UK general practice research database (GPRD).
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MATERIALS AND METHODS
We undertook a nested case–control study within the UK GPRD.
The GPRD collects data from around 500 general practices in the
United Kingdom, covers about 8% of the population and is broadly
representative of the UK population. The data obtained are
assessed in terms of completeness, continuity and plausibility, and
general practices that meet predefined standards are registered as
‘up to standard’ (UTS) practices. The information recorded in
GPRD includes demographic information, clinical diagnoses,
referral information, specialty consultation notes, results of
laboratory tests and hospital discharge information. The Read
and Oxford Medical Information System codes are used to classify
medical diagnoses. The GPRD also contains details of all
prescriptions issued for patients registered with the participating
practices (Garcı´a Rodrı´guez and Pe´rez Gutthann, 1998). The high
quality of GPRD prescription and diagnosis information has been
documented (Jick et al, 1991, 1992). Ethical approval for all
observational research using GPRD data has been obtained from a
multicentre research ethics committee.
Study population
The study included patients from UTS practices with diagnostic
codes for primary malignant neoplasia of the exocrine pancreas,
with a date of diagnosis/index date (first recorded occurrence of a
pancreatic cancer code) between January 1995 and June 2006. Data
were extracted from the GPRD in February 2007. Patients aged 85
or older were excluded as were cases without at least 5 years of
UTS data collection prior to the index date. Controls with no
GPRD record of pancreatic cancer were selected and matched to
cases on year of birth, sex and general practice site. Controls also
had at least 5 years of UTS data collection before their index date
(date of pancreatic cancer diagnosis in their matched case). Up to
seven controls were matched for each case.
Review of cancer codes
Pancreatic cancer is difficult to conclusively diagnose without
histological or cytological examination of relevant specimens and
these specimens are often not available. Pancreatic cancer may
therefore be confused with primary malignancies in anatomically
related organs or with secondary tumours. In one UK cancer
registry (unrelated to this study), only 57% of the patients had
histological or cytological confirmation of their diagnosis (Kinnear
et al, 2005). Data on histological or cytological confirmation of
pancreatic cancer were not available from GPRD, at the time the
data were obtained, as there was no routine linkage to cancer
registries. In order to minimise misclassification of pancreatic
cancer within this study, all cancer codes recorded in the medical
records of potential cases were reviewed. Only cases with
consistently recorded pancreatic cancer codes were included. All
other cases, for example, patients with codes for both pancreatic
cancer and cholangiocarcinoma, or carcinoma of bile duct,
gallbladder and so on, and their matched controls were excluded
from the dataset. Periampullary tumours were also excluded. Cases
and controls with a prior history of cancer (at least one year before
the index date) were also identified by review of cancer codes.
These patients were flagged as having a previous cancer but were
not excluded from the dataset.
Exposure to PPIs/H2RAs
The primary exposures of interest were PPI and H2RA use since
entry into the database until 2 years before the index date.
PPIs/H2RAs were defined as listed in the British National
Formulary 2009 (British Medical association and Royal Pharma-
ceutical Society of Great Britain, 2009), a national reference source
for information on drugs. A priori, we decided that a positive
association between pancreatic cancer risk and use of antisecretory
drugs, in the 2 years preceding the index date, may be observed
as pancreatic cancer symptoms often present as non-specific
abdominal symptoms and antisecretory drugs may have been used
to alleviate these symptoms. As a result, PPI/H2RA use in the 2
years before diagnosis was excluded from the analyses. PPI/H2RA
use individually in the 5 years before the index date (excluding the
2 years before) was also examined, as well as combined dose and
duration of PPI/H2RA use since entry into the database. The total
exposure (dose and duration) to antisecretory drugs (PPIs and
H2RAs) was also examined. The drug history for subjects in the
study population was reviewed and data were extracted on all PPIs/
H2RAs prescribed for cases and controls. PPI/H2RA use was
expressed in units of defined daily dose (DDD), a validated
measure of drug consumption maintained by the World Health
Organisation. It is the assumed average maintenance dose per day
of a drug that is used for its main indication in adults (World
Health Organisation Working Group, 2008), as the DDD of a drug
may be assumed to be functionally equivalent to the DDD of any
other drug used for a similar purpose.
The number of DDDs for each PPI/H2RA prescription issued
was calculated by multiplying the dose of the PPIs/H2RAs
prescribed by the quantity given and dividing this by the DDD
value assigned to that drug. For each time period under study, the
total number of DDDs, for each PPI/H2RA prescribed, and for all
PPIs/H2RAs combined, were calculated for each case and control.
Total dose of PPIs/H2RAs (expressed in DDDs), in the periods
under study, were categorized into approximate quartiles on the
basis of total PPI/H2RA use within the controls. Cumulative
duration of any PPI/H2RA use was calculated as the total number
of intended treatment days. Total duration of any PPI/H2RA use, in
the periods under study, was also categorized into approximate
quartiles, on the basis of duration of treatment within the controls.
Exposure to PPIs/H2RAs at any time prior to the index date
excluding the 2 years before the index date was further categorized
according to both dose and duration of use. The median number of
DDDs, per day, of PPI/H2RA exposure in the controls during this
period was 1 DDD per day, therefore low dose PPI/H2RA exposure
was classified as the use ofo1.0 DDD of PPIs/H2RAs per day and
high dose as 41.0 DDDs per day. Categories for duration of low
and high PPIs/H2RAs use were subsequently created; no use or use
for o1 year, use for 1 –3 years, use for 3– 5 years and use for X5
or more years (Yang et al, 2007). The total use of PPIs and H2RAs
was calculated by summing the total number of DDDs/days of use
since entry into the database.
Statistical analysis
Conditional logistic regression was used to calculate odds ratios
(ORs) and 95% confidence intervals (CIs) for the associations
between disease status and use of PPIs/H2RAs. Models were
constructed for ever/never use of all PPIs/H2RAs separately. Dose
and duration of PPI/H2RA use was examined using continuous
variables (output expressed per 100 DDDs and 100 days of use),
approximate quartiles of dose and duration of PPIs/H2RAs use
and the combined dose and duration variable. A model detailing
total exposure to antisecretory drugs (PPIs and H2RAs) was
also generated. For presentation purposes the output from the
continuous variables was reported per 100 DDDs and 100
days.PPI/H2RA use in the 2 years before diagnosis was excluded
in all analyses and models were constructed relating to the period
since entry into the GPRD and the 5 years before diagnosis/index
date.
All analyses were adjusted for potential confounders, including
smoking status (unknown, current smoker, non-smoker and
ex-smoker), body mass index (unknown, underweight, normal,
overweight and obese) according to the World Health Organisation
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categories (World Health Organisation Working Group, 2009),
alcohol use (unknown, current drinker, lifelong non-drinker and
ex-drinker), history of pancreatitis, history of diabetes and history of
cancer. For smoking, alcohol use and body mass index, the most
recent record excluding those within the year prior to the index date
was used and for history of diabetes, pancreatitis and cancer we also
excluded events within the year prior to the index date. Use of
nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin (ever/
never) was accounted for as users are increasingly likely to receive a
PPI/H2RA for prevention of NSAID-induced ulceration in the
GI tract (National Institute for Health and Clinical Excellence,
2008). NSAID/aspirin use has been associated with a reduced risk of
pancreatic cancer (Anderson et al, 2002). Use of systemic steroids
(ever/never use) and hormone replacement therapy (ever/never use)
was accounted for, as use of these drugs may confound the
association between PPI/H2RA and pancreatic cancer. Use of
NSAIDs/aspirin, hormone replacement therapy and steroids, in the
year before diagnosis, was excluded. Test for trends across categories
of dose and duration, where appropriate, was performed. Data on the
confounders were not available for all subjects and for those subjects
for whom all data were available, a restriction analyses was carried
out. All P-values were two sided. STATA Version 9 (Timberlake
Consultants Ltd, London, UK) was used for all analyses.
RESULTS
Within the UK GPRD, 1361 pancreatic cancer cases met our initial
inclusion criteria and these were matched to 9487 controls. After
review of cancer codes, 220 cases (16%) and their controls (1542)
were excluded, leaving 1141 pancreatic cancer cases and 7954
matched controls. Each case had at least one matched control and
490% of cases had seven matched controls. The mean duration of
UTS follow-up was 10.6 years (s.d., 3.4) for both cases and
controls. The mean age at database enrolment was identical for
cases and controls at 57.3 years (s.d., 9.8). Over 50% (53.7%) of all
study subjects were male (Table 1). The risk of pancreatic cancer
was elevated among smokers in our study population OR (95% CI)
1.92 (1.63– 2.26) and the OR for pancreatic cancer among subjects
with diabetes was 1.90 (95% CI: 1.53– 2.35). Any use of a PPI since
entry into the GPRD (excluding the 2 years prior to diagnosis) was
not associated with the risk of pancreatic cancer, OR (95%CI) 1.02
(0.85–1.22). There was no overall association between pancreatic
cancer risk and the total dose of PPI used since entry into the
GPRD. The adjusted ORs (95% CI) for an increase in 100 DDDs of
PPIs in this period was 0.99 (0.97– 1.01). When the dose of PPIs
was categorised according to use in controls (approximate
quartiles), no association was seen between dose category and
pancreatic cancer risk (Table 2). Similar results were observed in
the period of 5 years before the index date (excluding the 2 years
prior to diagnosis) (data not shown).
Duration of PPI use was examined in a similar manner to
dose and no associations with pancreatic cancer risk were seen
(Table 3).
Dose and duration of PPI use combined was not associated with
pancreatic cancer risk, although there was a suggestion of a
reduced risk of pancreatic cancer among those using lower doses
of PPIs (Table 4).
No overall association was found between pancreatic cancer
risk and the dose and duration of H2RAs used since entry into
the GPRD (Data not shown). Similar results were seen for use in
the 5 years before the index date. The analysis that combined
dose and duration of H2RA use demonstrated an increased risk
of pancreatic cancer, OR (95%CI) 1.25 (1.03–1.52), among short-
term users (0–1 years) of high-dose H2RAs. However, no increases
in risk were seen among those using high-dose H2RAs for longer
durations of time and the number of these users was small
(Table 4).
The total dose and duration of antisecretory drug use combined
(PPI plus H2RA use) was not associated with pancreatic cancer risk
either in the period since entry into the GPRD (Table 5). The
results from the restriction analysis completed for all subjects with
complete data on confounders showed that the absence of data on
some confounders, did not affect the overall estimates (data not
shown).
DISCUSSION
In this large population-based study, no association between risk
of pancreatic cancer and antisecretory drug use was seen for ever
Table 1 Characteristics of cases and controls
Cases
(n¼ 1141)
Controls
(n¼ 7954) P-value
Mean age at database
enrolment (year) (s.d.)
57.3 (9.8) 57.3 (9.8) 40.99
Male sex (%) 53.7 53.7 40.99
Mean duration of follow-up
before index date (year) (s.d.)
10.6 (3.4) 10.6 (3.4) 40.99
Smoking status o0.01
Current smoker 302 (26.5%) 1372 (17.3%)
Non-smoker 463 (40.6%) 3961 (49.8%)
Ex-smoker 235 (20.6%) 1499 (18.9%)
Missing data 141 (12.4%) 1122 (14.1%)
BMI (kgm2) 0.1
o18.5 16 (1.4%) 102 (1.3%)
X18.5 and o25 353 (31.0%) 2323 (29.2%)
X25 and o30 343 (30.1%) 2525 (31.8%)
X30 187 (16.4%) 1108 (13.9%)
Missing 242 (21.21%) 1896 (23.8%)
Current drinking status 0.4
Current drinker 731 (64.1%) 4992 (62.8%)
Non-drinker 165 (14.5%) 1107 (13.9%)
Ex-drinker 7 (0.6%) 77 (1.0%)
Missing data 238 (20.9%) 1778 (22.4%)
HRT use 0.3
Never 1095 (95.9%) 7574 (95.2%)
Ever 46 (4.1%) 380 (4.8%)
Steroid use 0.2
Never 990 (86.8%) 6999 (88.0%)
Ever 151 (13.2%) 955 (12.0%)
Pancreatitis o0.01
Never 1085 (95.1%) 7901 (99.3%)
Ever 56 (4.9%) 53 (0.7%)
PPI use 0.27
Never 964 (84.5%) 6817 (85.7%)
Ever 177 (15.5%) 1137 (14.3%)
H2RA use o0.01
Never 877 (76.9%) 6423(80.8%)
Ever 264 (23.1%) 1531 (19.2%)
Diabetes o0.01
Never 1006 (88.2%) 7442 (93.56%)
Ever 135 (11.8%) 512 (6.44%)
Prior cancer 0.35
Never 1049 (91.9%) 7374 (92.7%)
Ever 92 (8.1%) 580 (7.3%)
Abbreviations: BMI¼ body mass index; H2RA¼ histamine-2-receptor antagonist;
HRT¼ hormone replacement therapy; PPI¼ proton pump inhibitor.
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compared with non-use of PPIs or H2RAs. There was also no
overall association between pancreatic cancer risk and the total
dose or duration of PPIs or H2RAs used and no increases in risk
were seen among subjects who used these drugs at the highest
doses or for the longest durations. No consistent patterns of
association were seen when cumulative exposure (dose and
duration) to these drugs were examined separately or together
(total antisecretory drug use, i.e., PPI plus H2RA), although there
was some evidence of a decrease in risk among low-dose PPI users
and an increase in risk among short-term low-dose H2RA users.
Overall, this study does not provide consistent evidence for either
an increased or decreased risk of pancreatic cancer associated with
the use of PPIs or H2RAs. However, few study subjects had long-term
exposure to PPIs. Just 16 cases and 122 controls used PPIs (at low or
high doses) for longer than 4 years. More profound suppression of
acid and subsequent hypergastrinaemia, which occurs with higher
doses of PPIs, is biologically more likely to affect pancreatic cancer
risk. However, in this study no increased risk of pancreatic cancer
was observed among long-term (44 years) high-dose PPI users, but
the number of long-term high-dose PPI users (11 cases, 61 controls)
was too small to adequately assess the effect of high doses of these
drugs on pancreatic cancer risk.
Certain PPIs were not available in the United Kingdom until
2000 (UK Medicines Information Pharmacist groups, 2001) and
Table 2 Total dose of PPI, H2RA and risk of pancreatic cancer
PPI use
Entry into GPRD until 2 years before index date H2RA use Entry into GPRD until 2 years before index date
Dose of PPI use
(DDDs)
Cases
(n)
Controls
(n)
OR
(95% CI)
Adjusted OR
(95% CI)a
Dose of H2RA
use (DDDs)
Cases
(n)
Controls
(n)
OR
(95% CI)
Adjusted OR
(95% CI)a
Category 1 (no use) 964 6817 1.0 1.0 Category 1 (no use) 877 6423 1.0 1.0
Category 2 (0 – 28) 52 311 1.19 (0.88 – 1.61) 1.14 (0.84 – 1.55) Category 2 (0 – 30) 83 464 1.31 (1.03 – 1.69) 1.30 (1.01 – 1.68)
Category 3 (28.5 – 112) 31 257 0.86 (0.59 – 1.25) 0.79 (0.54 – 1.17) Category 3 (30.5 – 90) 53 316 1.24 (0.92 – 1.68) 1.15 (0.84 – 1.56)
Category 4 (112.5 – 476) 51 288 1.26 (0.93 – 1.72) 1.14 (0.83 – 1.56) Category 4 (90.5 – 480) 67 370 1.34 (1.02 – 1.76) 1.20 (0.91 – 1.59)
Category 5 (4476) 43 281 1.09 (0.78 – 1.52) 0.96 (0.68 – 1.36) Category 5 (4480) 61 381 1.18 (0.89 – 1.57) 1.05 (0.78 – 1.40)
Abbreviations: BMI¼ body mass index; CI¼ confidence interval; DDD¼ defined daily dose; H2RA¼ histamine-2-receptor antagonist; HRT¼ hormone replacement therapy;
NSAID¼ nonsteroidal anti-inflammatory drug; OR¼ odds ratio; PPI¼ proton pump inhibitor. aAdjusted for smoking status (current smoker, non-smoker, ex-smoker, missing
data), BMI (o18.5,X18.5,o25,X25,o30 andX30 kgm2, missing), alcohol use (current drinker, non-drinker, ex-drinker), history of chronic pancreatitis (ever/never), use of
other drugs (NSAIDs, steroids and HRT (ever/never)), diabetes (ever/never) and prior cancer (ever/never).
Table 3 Duration of PPI, H2RA use and risk of pancreatic cancer
PPI use
Entry into GPRD until 2 years before index date H2RA use Entry into GPRD until 2 years before index date
Duration of PPI use
(days)
Cases
(n)
Controls
(n)
OR
(95% CI)
Adjusted OR
(95%CI)a
Duration of
H2RA use (Days)
Cases
(n)
Controls
(n)
OR
(95% CI)
Adjusted OR
(95% CI)a
-Category 1 (no use) 964 6817 1.0 1.0 -Category 1 (no use) 877 6424 1.0 1.0
-Category 2 (0 – 28) 51 308 1.18 (0.87 – 1.60) 1.13 (0.83 – 1.55) -Category 2 (0 – 30) 80 449 1.31 (1.02 – 1.69) 1.30 (1.01 – 1.69)
-Category 3 (28.5 – 106) 37 264 1.0 (0.70 – 1.42) 0.92 (0.64 – 1.32) -Category 3 (30.5 – 90) 57 320 1.32 (0.98 – 1.77) 1.20 (0.89 – 1.63)
-Category 4 (106.5 – 552) 47 281 1.20 (0.87 – 1.65) 1.07 (0.77 – 1.48) -Category 4 (90.5 – 520) 71 379 1.39 (1.06 – 1.81) 1.26 (0.96 – 1.65)
-Category 5 (4552) 42 284 1.05 (0.75 – 1.47) 0.93 (0.65 – 1.32) -Category 5 (4520) 56 382 1.08 (0.81 – 1.44) 0.95 (0.71 – 1.29)
Abbreviations: BMI¼ body mass index; CI¼ confidence interval; DDD¼ defined daily dose; H2RA¼Histamine-2-receptor antagonist; HRT¼ hormone replacement therapy;
NSAID¼ nonsteroidal anti-inflammatory drug; OR¼ odds ratio; PPI¼ proton pump inhibitor. aAdjusted for smoking status (current smoker, non-smoker, ex-smoker, missing
data), BMI (o18.5,X18.5,o25,X25,o30 andX30 kgm2 , missing), alcohol use (current drinker, non-drinker, ex-drinker), history of chronic pancreatitis (ever/never), use of
other drugs (NSAIDs, steroids and HRT (ever/never)), diabetes (ever/never) and prior cancer (ever/never).
Table 4 Pancreatic cancer risk according to dose and duration of PPI, H2RA use since entry into GP
o1.0 DDD per day X1.0 DDD per day
Cases n Controls n OR (95% CI)
Adjusted OR
(95%CI)a Cases n Controls n OR (95% CI)
Adjusted OR
(95%CI)a
(a) PPI
Duration of PPI use
Nonusers 964 6817 1.0 1.0 964 6817 1.0 1.0
0–1 year 20 195 0.70 (0.44–1.12) 0.60 (0.37–0.98) 107 592 1.27 (1.02–1.58) 1.20 (0.95–1.50)
1–4 years 14 113 0.87 (0.50–1.54) 0.70 (0.39–1.27) 20 115 1.23 (0.76–1.99) 1.08 (0.65–1.77)
44 years 5 61 0.61 (0.24–1.53) 0.54 (0.20–1.42) 11 61 1.32 (0.69–2.55) 1.32 (0.67–2.60)
(b) H2RA
Duration of H2RA use
Nonusers 877 6424 1.0 1.0 877 6424 1.0 1.0
0–1 years 29 193 1.09 (0.72–1.63) 0.98 (0.65–1.49) 163 887 1.34 (1.12–1.61) 1.25 (1.03–1.52)
1–4 years 13 109 0.91 (0.5–1.63) 0.92 (0.51–1.68) 36 190 1.40 (0.97–2.01) 1.24 (0.84–1.81)
44 years 9 80 0.96 (0.47–1.96) 0.82 (0.39–1.72) 14 71 1.54 (0.86–2.77) 1.35 (0.73–2.48)
Abbreviations: BMI¼ body mass index; CI¼ confidence interval; DDD¼ defined daily dose; H2RA¼ histamine-2-receptor antagonist; HRT¼ hormone replacement therapy;
NSAID¼ nonsteroidal anti-inflammatory drug; OR¼ odds ratio; PPI¼ proton pump inhibitor. aAdjusted for smoking status (current smoker, non-smoker, ex-smoker, missing
data), BMI (o18.5,X18.5,o25,X25,o30 andX30 kgm2 , missing), alcohol use (current drinker, non-drinker, ex-drinker), history of chronic pancreatitis (ever/never), use of
other drugs (NSAIDs, steroids and HRT (ever/never)), diabetes (ever/never) and prior cancer (ever/never).
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the dates of data capture in this study appear to have preceded the
rapid increase in use of PPIs in recent years. Pancreatic
carcinogenesis has a long latency period (Brat et al, 1998),
therefore it may be too early to see a relationship between use of
PPIs and pancreatic cancer development due to their relatively
recent introduction to the UK market.
Since the introduction of PPIs, use of H2RAs has declined
(National Health Service Business Services Authority, 2009),
however, it was deemed possible that some users may have been
exposed to H2RAs for prolonged periods of time and this may be
important for cancer risk. Despite the earlier introduction of
H2RAs to the UK market (in the mid 1970s), there were very few
long-term (44 years) H2RA users (23 cases and 151controls)
compared with short-term users (192 cases, 1080 controls) in this
study. As PPIs provide a more rapid and sustained increase in
gastric pH (Brett, 2005), long-term H2RA users may have switched
to PPI therapy in recent years, resulting in the reduced number of
long-term H2RA users.
Epidemiological studies have shown an increased risk of gastric
cancer among PPI users (Bateman et al, 2003; Garcı´a Rodrı´guez
et al, 2006; Poulsen et al, 2009), however, any effect may have been
due to reverse causality or confounding by indication. The
increasing use of PPIs, in the last decade, was thought to have
been related to the sharp rise in oesophageal cancer incidence
(Lepage et al, 2008; Rosch, 2010). However, increased incidence,
along with the higher mortality rates for oesophageal cancer, was
attributed to the underlying disease and not to treatment with PPIs
(Bateman et al, 2003; Garcı´a Rodrı´guez et al, 2006); Robertson
et al, 2007). No association between PPI use and colorectal cancer
has been observed in large case–control studies (Yang et al, 2007;
Van soest et al, 2008).
Assessment of the relationship between PPI/H2RA use and
pancreatic cancer risk is likely to be complicated by the underlying
indications for use of these drugs. Epidemiological studies have
found an increased risk of pancreatic cancer among individuals
with duodenal ulcers, gastric ulcers or peptic ulcers (indica-
tions for which these drugs are used) (Farrow and Davis, 1990;
Luo et al, 2007), whereas others have failed to show an associa-
tion (La Vecchia et al, 1990; Silverman et al, 1999). Helicobacter
pylori infection is a leading cause of peptic ulcers and has
been shown to be associated with pancreatic cancer risk
(Stolzenberg-Solomon et al, 2001) as was partial gastrectomy and
truncal vagotomy, which are surgical procedures used in the
treatment of peptic ulcer disease (Tersmette et al, 1990; van Rees
et al, 1999; Tascilar et al, 2002). However, conflicting results
have been reported (Caygill et al, 1987; La Vecchia et al, 1990;
Silverman et al, 1999).
This investigation has several key strengths. It is the only study
to date to assess the association of PPI/H2RA exposure and
pancreatic cancer. A detailed analysis was possible by stratifying
the analyses based on dose, duration, and dose and duration of
PPI/ H2RA use. The use of prospectively collected prescription
data avoids errors of recall and potential recall bias. All subjects in
our study had at least 5 years of data available prior to pancreatic
cancer diagnosis and data were available prior to diagnosis for a
mean of over 10 years. We also adjusted for all major confounders
and, although data were not available for all subjects, the results
of restriction analyses, including only those patients who had data
on these confounders, were not different from the main analyses.
The results for the association between pancreatic cancer and
smoking and diabetes reported in this study are similar to those
obtained in some larger international studies (Heinen et al, 2010;
Bertuccio et al, 2011; Lipworth et al, 2011), which supports the
validity of our study.
However, the study has some limitations. A low prevalence of
long-term PPI/H2RA use in the study population meant that we
were unable to examine the effects of exposure to these agents for
long periods of time. Data on prescriptions issued may not reflect
actual use of PPIs/H2RAs, but there is no reason to believe that
noncompliance with prescription medication would be system-
atically different between cases and controls. No information was
available on over-the-counter PPI/H2RA use and misclassification
of over-the-counter users as nonusers based on prescription
information would have biased the estimates towards the null.
However, at the time of this study there was only one PPI-available
over-the-counter from pharmacies in the United Kingdom and
uptake has been low (Stewart et al, 2007), although H2RAs are
more readily available. Pancreatic cancer diagnoses were not
validated in this study and any misclassification of diagnosis is
likely to bias the estimate towards the null. However, we excluded
very elderly subjects, in whom diagnostic accuracy may be a
particular problem, and all cancer codes were reviewed and cases
with inconsistent coding were excluded. Furthermore, cancer
diagnoses in GPRD appear to be a reliable record of incident
cancer diagnoses and have been shown to concord with original
medical records in 95% of cases (Jick et al, 1997).
In summary, despite biologically plausible mechanisms, where-
by use of PPIs or H2RAs may increase the risk of pancreatic cancer,
we did not observe any consistent associations between use of
these drugs and pancreatic cancer risk in a large study involving a
representative UK population.
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Table 5 Pancreatic risk according to total dose and duration of acidsuppressive therapy (PPIs and H2RAs) since entry into the GPRD
PPIs and H2Ras
Entry into GPRD until 2 years before index date
PPIs and H2RAs
Entry into GPRD until 2 years before index date
Dose (DDDs) Cases Controls
Adjusted OR
(95% CI)a Duration (Days) Cases Controls
Adjusted OR
(95% CI)a
No use 818 5966 1.0 -No use 818 5968 10
Category 2 (0–30) 77 500 1.12 (0.86–1.45) -Category 2 (0–37) 78 502 1.15 (0.89–1.49)
Category 3 (31–144) 81 496 1.12 (0.87–1.44) -Category 3 (37–144) 84 492 1.14 (0.89–1.47)
Category 4 (145–776) 89 495 1.21 (0.95–1.55) -Category 4 (145–849) 84 496 1.16 (0.90–1.49)
Category 5 (4776) 76 497 0.97 (0.74–1.27) -Category 5 (4849) 77 496 1.03 (0.79–1.35)
Abbreviations: BMI¼ body mass index; CI¼ confidence interval; DDD¼ defined daily dose; H2RA¼Histamine-2-receptor antagonist; HRT¼ hormone replacement therapy;
NSAID¼ nonsteroidal anti-inflammatory drug; OR¼ odds ratio; PPI¼ proton pump inhibitor. aAdjusted for smoking status (current smoker, non-smoker, ex-smoker, missing
data), BMI (o18.5,X18.5,o25,X25,o30 andX30 kgm2, missing), alcohol use (current drinker, non-drinker, ex-drinker), history of chronic pancreatitis (ever/never), use of
other drugs (NSAIDs, steroids and HRT (ever/never)), diabetes (ever/never) and prior cancer (ever/never).
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